Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 35 citing articles:

Grade ≥ 3 hematologic adverse events of immunotherapy in advanced NSCLC patients: a systematic review and meta-analysis
Shuang Wang, Meng‐Ting Cai, Yajun Xiong, et al.
European Journal of Clinical Pharmacology (2025)
Closed Access | Times Cited: 1
Identification and Application of Emerging Biomarkers in Treatment of Non-Small-Cell Lung Cancer: Systematic Review
Juan Carlos Restrepo, Darly Martínez Guevara, Andrés Pareja López, et al.
Cancers (2024) Vol. 16, Iss. 13, pp. 2338-2338
Open Access | Times Cited: 8
PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial
Si‐Yang Maggie Liu, Jie Huang, Jia‐Yi Deng, et al.
Science Bulletin (2023) Vol. 69, Iss. 4, pp. 535-543
Open Access | Times Cited: 16
Cost-effectiveness of immunotherapies for advanced squamous non-small cell lung cancer: a systematic review
Minyu Cheng, Yanfei Shao, Li Li, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 5
WDR62 mediates MAPK/ERK pathway to stimulate DNA damage repair and attenuate cisplatin sensitivity in lung adenocarcinoma
Li Xu, Yingwei Guo, Zecheng Qi, et al.
Anti-Cancer Drugs (2025)
Closed Access
Optimal early endpoint for second-line or subsequent immune checkpoint inhibitors in previously treated advanced solid cancers: a systematic review
Jingqiu Li, Xiaoding Zhou, Lei Wu, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Severe thyroiditis induced by sintilimab monotherapy in a patient with non-small cell lung cancer: a case report and literature review
Xiaolin Zhao, Xiaoyu Wang, Surui Liu, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Intermediate endpoints as surrogates for outcomes in cancer immunotherapy: a systematic review and meta-analysis of phase 3 trials
Zhishan Zhang, Qunxiong Pan, Mingdong Lu, et al.
EClinicalMedicine (2023) Vol. 63, pp. 102156-102156
Open Access | Times Cited: 10
Association Between Sex and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta Analysis
Jianxiong Lai, Xiaohong Kuang, Yi Fu, et al.
Immunotherapy (2024) Vol. 16, Iss. 7, pp. 481-495
Closed Access | Times Cited: 3
Adverse events associated with immune checkpoint inhibitors in non-small cell lung cancer: a safety analysis of clinical trials and FDA pharmacovigilance system
Xueyan Liang, Hewei Xiao, Huijuan Li, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
Case report: Robust response to sintilimab in advanced distal cholangiocarcinoma with PD-L1 expression and DNA damage repair
Wenguang He, Congcong Song, Jiwei Ren, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 2
Association of PD-L1 expression with survival benefit from PD-1/PD-L1 inhibitors in advanced cancer: Systematic review and meta-analysis of phase III randomized clinical trials
Xiaohong Kuang, Run Xu, Jian Li
Critical Reviews in Oncology/Hematology (2024) Vol. 198, pp. 104357-104357
Closed Access | Times Cited: 2
The risk of endocrine immune-related adverse events induced by PD-1 inhibitors in cancer patients: a systematic review and meta-analysis
Pengfei Zhao, Ting Zhao, Lihong Yu, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 2
The co‐location of CD14+APOE+ cells and MMP7+ tumour cells contributed to worse immunotherapy response in non‐small cell lung cancer
Guangyu Fan, Tongji Xie, Le Tang, et al.
Clinical and Translational Medicine (2024) Vol. 14, Iss. 9
Open Access | Times Cited: 2
PD-1/PD-L1 inhibitors plus anti-angiogenic agents with or without chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy as second or later-line treatment for patients with advanced non-small cell lung cancer: A real-world retrospective cohort study
Shubin Chen, Haowen Wei, Wenhua Zhao, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 10
Preparation of a Novel Multifunctional Cationic Liposome Drug-carrying System and its Functional Study on Lung Cancer
Yi Kong, Li Xu, Jun Cao
Anti-Cancer Agents in Medicinal Chemistry (2024) Vol. 24, Iss. 14, pp. 1085-1095
Closed Access | Times Cited: 1
Sintilimab in combination with stereotactic body radiotherapy and granulocyte-macrophage colony-stimulating factor in metastatic non-small cell lung cancer: The multicenter SWORD phase 2 trial
Jianjiao Ni, Xiaofei Wang, Lin Wu, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Spatial analyses revealed S100P + TFF1 + tumor cells in spread through air spaces samples correlated with undesirable therapy response in non-small cell lung cancer
Guangyu Fan, Tongji Xie, Mengwei Yang, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 1
Sintilimab plus HPV vaccine for recurrent or metastatic cervical cancer
Buhai Wang, Yichen Liang, Yuechao Wu, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 11, pp. e009898-e009898
Open Access | Times Cited: 1
Efficacy of bevacizumab through an indwelling pleural catheter in non-small cell lung cancer patients with symptomatic malignant pleural effusion
Hao Zeng, Yuanyuan Zhang, Sihan Tan, et al.
BMC Pulmonary Medicine (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Economic evaluation of sintilimab versus docetaxel as second-line treatment for patients with advanced or metastatic squamous non-small-cell lung cancer in China: a model-based cost-effectiveness analysis
Mochong Liao, Shuo Kang
Expert Review of Pharmacoeconomics & Outcomes Research (2023) Vol. 24, Iss. 1, pp. 161-166
Closed Access | Times Cited: 2
Landscape of the clinical development of China innovative anti-lung cancer drugs
Yuankai Shi
Cancer Pathogenesis and Therapy (2022) Vol. 1, Iss. 1, pp. 67-75
Open Access | Times Cited: 3
[Chinese Expert Consensus on Second-line Treatment for Non-small Cell Lung Cancer with Negative Driver Gene Mutations].

PubMed (2024) Vol. 27, Iss. 2, pp. 81-87
Closed Access
Clinical effect of anlotinib in combination with docetaxel in treating advanced non-small cell lung cancer
Guibin Weng, Weimin Fang, Yijin Lin, et al.
Cellular and Molecular Biology (2024) Vol. 70, Iss. 4, pp. 212-216
Open Access
Page 1 - Next Page

Scroll to top